6533b871fe1ef96bd12d22c4

RESEARCH PRODUCT

Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.

Christiane Windemuth-kieselbachFrederik MarméMatthias W. BeckmannErich SolomayerEva-maria GrischkeMarcus SchmidtDirk StrumbergFrank Gerhard FoersterBernd GerberPeter KlareAndreas SchneeweissVolker Moebus

subject

OncologySorafenibCancer Researchmedicine.medical_specialtyChemotherapyBevacizumabbusiness.industrymedicine.medical_treatmentPharmacologyPlacebomedicine.diseaseMetastatic breast cancerOncologyDocetaxelInternal medicineMonoclonalMedicineIn patientbusinessmedicine.drug

description

1072 Background: Anti-angiogenic therapy with the monoclonal anti-VEGF antibody Bevacizumab (Bev) in combination with chemotherapy increases overall response rates (ORR) and progression free surviv...

https://doi.org/10.1200/jco.2014.32.15_suppl.1072